Alfa Cytology congratulated the 9th International Conference on Cancer Research and Drug Development passed off perfectly.

CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – ...

“Whether it is fair or not, places like San Francisco and Oregon have become poster children for failed drug ... Trump and ...

Viking Therapeutics' VK2735 shows up to 8.2% weight loss in a 28-day oral dosing trial. Phase 2 VENTURE trial reports up to 14.7% weight loss over 13 weeks with weekly VK2735 injections.

The Delhi Directorate of Education has partnered with Delhi Police to educate students about cybercrime. Schools will display ...

LEADING Austrian health experts gathered at UEG Week 2024 to push forward the implementation of a nationwide, quality-assured ...

This promising drug will be highlighted in a moderated poster presentation in the session entitled ... HBI-3000 may mitigate that trend because of its safety and efficacy, as many patients want to ...

Participants were broken into two cohorts. The first cohort received one of three doses of PCRX-201. The second cohort received concurrent pretreatment with an intraarticular corticosteroid ...

Ryan White desperately wanted to be normal. “All I ever wanted to do was to be one of the kids,” he recalled in his ...

demonstrated long-term efficacy and safety in patients with schizophrenia, long-term results from the phase III EMERGENT-4 trial showed. Participants who continued taking the drug after the ...

DiffuSphereTM is designed to enable precise drug delivery at therapeutic dose levels directly into target tissues, e ...